| Dr Zumilvette Ortiz Detres, MD | |
|
2757 Citrus Tower Blvd Ste 101, Clermont, FL 34711-6699 | |
| (352) 404-8108 | |
| (352) 404-8647 |
| Full Name | Dr Zumilvette Ortiz Detres |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Experience | 20 Years |
| Location | 2757 Citrus Tower Blvd Ste 101, Clermont, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861632200 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 17492 (Puerto Rico) | Secondary |
| 208D00000X | General Practice | ACN455 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Home Alliance, Llc | 6406096536 | 75 |
News Archive
Investigators for NHLBI's Cardiovascular Health Study compared the two measures of kidney function, cystatin-C and the standard test creatinine, as predictors of death from all causes, death from cardiovascular causes, and incidence of heart attack and stroke among 4,637 elderly participants in the study.
Zymeworks Inc. today announced a research collaboration with Merck, known as MSD outside the United States and Canada, around Zymeworks' proprietary Azymetric platform for the development of novel bi-specific antibody therapeutic candidates. Bi-specific antibodies are designed to bind to two different drug targets for broad use in clinical applications such as oncology or autoimmune disease.
For the first time scientists from Umeå University show the importance of DNA damage in fine tuning of our innate immune system and hence the ability to mount the optimal inflammatory response to infections and other biological dangers.
The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.
Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.
› Verified 7 days ago
| Entity Name | Medical Home Alliance, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740527811 PECOS PAC ID: 6406096536 Enrollment ID: O20130712000249 |
News Archive
Investigators for NHLBI's Cardiovascular Health Study compared the two measures of kidney function, cystatin-C and the standard test creatinine, as predictors of death from all causes, death from cardiovascular causes, and incidence of heart attack and stroke among 4,637 elderly participants in the study.
Zymeworks Inc. today announced a research collaboration with Merck, known as MSD outside the United States and Canada, around Zymeworks' proprietary Azymetric platform for the development of novel bi-specific antibody therapeutic candidates. Bi-specific antibodies are designed to bind to two different drug targets for broad use in clinical applications such as oncology or autoimmune disease.
For the first time scientists from Umeå University show the importance of DNA damage in fine tuning of our innate immune system and hence the ability to mount the optimal inflammatory response to infections and other biological dangers.
The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.
Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zumilvette Ortiz Detres, MD 6675 Westwood Blvd Ste 475, Orlando, FL 32821-6027 Ph: (407) 845-0330 | Dr Zumilvette Ortiz Detres, MD 2757 Citrus Tower Blvd Ste 101, Clermont, FL 34711-6699 Ph: (352) 404-8108 |
News Archive
Investigators for NHLBI's Cardiovascular Health Study compared the two measures of kidney function, cystatin-C and the standard test creatinine, as predictors of death from all causes, death from cardiovascular causes, and incidence of heart attack and stroke among 4,637 elderly participants in the study.
Zymeworks Inc. today announced a research collaboration with Merck, known as MSD outside the United States and Canada, around Zymeworks' proprietary Azymetric platform for the development of novel bi-specific antibody therapeutic candidates. Bi-specific antibodies are designed to bind to two different drug targets for broad use in clinical applications such as oncology or autoimmune disease.
For the first time scientists from Umeå University show the importance of DNA damage in fine tuning of our innate immune system and hence the ability to mount the optimal inflammatory response to infections and other biological dangers.
The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.
Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.
› Verified 7 days ago
Dr. Maria De Las Mercedes Vazquez Torres, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 3725 S Hwy 27 Ste 101, Clermont, FL 34711 Phone: 352-242-0676 Fax: 352-242-1335 | |
Norma Rosado, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 3130 Citrus Tower Blvd, Clermont, FL 34711 Phone: 407-931-0444 Fax: 407-962-4446 | |
Elder Antonio Arroyo-nieto, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 3725 S Hwy 27 Ste 101, Clermont, FL 34711 Phone: 352-524-2067 Fax: 352-242-1335 | |
Dr. Jessica Maisonave, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 1735 E Highway 50 Ste B, Clermont, FL 34711 Phone: 352-241-0549 Fax: 352-242-9325 | |
Dr. Janice Ramos Colon, MD General Practice Medicare: Medicare Enrolled Practice Location: 260 Mohawk Rd # 264, Clermont, FL 34715 Phone: 855-226-6633 Fax: 866-285-7068 | |
Fadi Elia Rahhal, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 821 Oakley Seaver Dr, Clermont, FL 34711 Phone: 352-242-1665 Fax: 352-243-1649 | |
Dr. Yodsui Linaida Llop, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 3130 Citrus Tower Blvd, Clermont, FL 34711 Phone: 407-931-0444 Fax: 407-962-4446 |